

Supplementary Material

Table of Contents

I. Supplementary Materials and Methods

Search strategy and results

Risk of bias

Publication bias

II. Supplementary Tables

III. Supplementary Figures

Supplementary Materials and Methods

1. Search strategy and results

(1) OVID-MEDLINE

No.	Keywords	Results
1	exp Non-alcoholic Fatty Liver Disease	13,319
2	Non?alcohol* Fatty Liver.tw	10,844
3	(non?alcohol* steatohepatitis OR NAFLD OR steatosis).tw	33,228
4	OR/1-3	37,617
5	(FIB-4 OR fibrosis-4 index OR NAFLD fibrosis score).tw	1,555
6	4 AND 5	
7	(Randomized Controlled Trials as Topic/ or randomized controlled trial/ or Random Allocation/ or Double Blind Method/ or Single Blind Method/ or clinical trial/ or clinical trial, phase i.pt. or clinical trial, phase ii.pt. or clinical trial, phase iii.pt. or clinical trial, phase iv.pt. or controlled clinical trial.pt. or randomized controlled trial.pt. or multicenter study. pt. or clinical trial.pt. or exp Clinical Trials as topic/ or (clinical adj trial*).tw. or ((singl* or doubl* or treb* or tripl*) adj (blind*3 or mask*3)).tw. or PLACEBOS/ or placebo*.tw. or randomly allocated.tw. or (allocated adj2 random*).tw.) not (case report.tw. or letter/ or historical article/)	1,644,777
8	Epidemiologic Studies/ or exp Case Control Studies/ or exp Cohort Studies/ or Case-control.tw. or (cohort adj (study or studies)).tw. or Cohort analy\$.tw. or (Follow up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw. or Retrospective.tw.or Cross sectional.tw. or Cross-sectional studies/	3,135,261
9	OR/7-8	4,351,134
10	6 AND 9	322

(2) OVID-EMBASE

No.	Keywords	Results
1	exp nonalcoholic fatty liver/	46,820
2	Non?alcohol* Fatty Liver.tw	16,443
3	(non?alcohol* steatohepatitis OR NAFLD OR steatosis).tw	57,251
4	OR/1-3	72,477
5	(FIB-4 OR fibrosis-4 index OR NAFLD fibrosis score).tw	3,833
6	4 AND 5	1,638
7	(Clinical Trial/ OR Randomized Controlled Trial/ OR controlled clinical trial/ OR multicenter study/ OR Phase 3 clinical trial/ OR Phase 4 clinical trial/ OR exp RANDOMIZATION/ OR Single Blind Procedure/ OR Double Blind Procedure/ OR Crossover Procedure/ OR PLACEBO/ OR randomi?ed controlled trial\$.tw. OR rct.tw. OR (random\$ adj2 allocat\$).tw. OR single blind\$.tw. OR double blind\$.tw. OR ((treble or triple) adj blind\$).tw. OR placebo\$.tw. OR Prospective Study/) not (Case Study/ OR case report.tw. OR abstract report/ or letter/ OR Conference proceeding.pt. OR Conference abstract.pt. OR Editorial.pt. OR Letter.pt. OR Note.pt.)	1,799,598
8	Clinical study/ OR Case control study OR Family study/ OR Longitudinal study/ OR Retrospective study OR (Prospective study/ not Randomized controlled trials/) OR Cohort analysis/ OR (Cohort adj (study or studies)).mp. OR (Case control adj (study or studies)).tw.OR (follow up adj (study or studies)).tw.OR (observational adj (study or studies)).tw.OR (epidemiologic\$ adj (study or studies)).tw. OR (cross sectional adj (study or studies)).tw.	2,955,206
9	OR/7-8	4,169,300
10	6 AND 9	818

(3) Cochrane Library

No.	Keywords	Results
1	[mh "Non-alcoholic Fatty Liver Disease"]	971
2	["Nonalcohol* Fatty Liver" OR "Non-alcohol* Fatty Liver" OR "Non alcohol* Fatty Liver"]	7
3	["non?alcohol* steatohepatitis" OR NAFLD OR steatosis]	2,608
4	{OR #1-#3}	2,940
5	(FIB-4 OR fibrosis-4 index OR NAFLD fibrosis score)	377
6	#4 AND #5	286

(4) KMBASE


No.	Keywords	Results
1	(((ALL=Non-alcoholic Fatty Liver] AND [ALL=FIB-4])	8
2	([ALL=Non-alcoholic Fatty Liver] AND [ALL=fibrosis-4])	7

(5) KISS

No.	Keywords	Results
1	Non-alcoholic Fatty Liver AND FIB-4	153
2	Non-alcoholic Fatty Liver AND fibrosis-4	141

4. Risk of bias


(1) QUADAS tool



	Risk of bias			Applicability concerns			
	Patient selection	Index test	Reference standard	Flow and timing	Patient selection	Index test	Reference standard
Aida 2015	?	●	●	●	?	?	●
Anstee 2019	?	●	●	●	?	●	●
Balakrishnan 2020	●	●	●	●	●	●	●
Boursier 2019	●	●	●	●	●	?	●
Carli 2019	●	●	?	?	●	●	●
Chan 2015	●	●	●	●	●	●	●
Chan 2019	●	●	●	●	●	●	●
Cui 2015	●	●	●	●	●	●	●
Demir 2013	●	●	●	●	●	●	●
Goh 2015	●	●	●	●	●	●	●
Gutierrez 2013	●	●	●	●	●	●	●
Joo 2018	●	●	●	●	●	●	●
Jun 2017	●	●	●	●	●	●	●
Kakisaka 2018	●	●	●	●	●	●	●
Kao 2020	?	●	●	●	?	?	●
Kaya 2019	●	●	●	●	●	●	●
Kim 2013	●	●	●	●	●	?	●
Labenz 2018	●	●	●	●	●	●	●
Lang 2020	●	●	●	●	?	?	●
Lum 2020	●	●	●	●	●	●	●
McPherson 2013	●	●	●	●	?	●	●
Meneses 2020	●	●	●	●	?	●	●
Nasr 2016	●	●	●	●	●	?	●
Ooi 2017	●	●	●	?	?	●	●
Patel 2018	?	●	●	●	?	●	●
Petta 2015	?	●	●	●	●	●	●
Petta 2019	●	●	●	●	●	●	●
Siddiqui 2019	?	●	●	●	●	●	●
Singh 2020	●	●	●	●	?	●	●
Treepasertsuk 2016	●	●	●	●	●	●	●
Wong 2008	●	●	●	●	●	●	●
Wong 2010	●	●	●	●	●	?	●
Xun 2012	●	●	●	●	●	●	●
Yang 2019	●	●	●	●	●	●	●
Yoneda 2013	●	●	●	●	?	●	●
Zhou 2019	●	●	●	●	●	●	●

● High ? Unclear ● Low





(2) QUIPS tool



	Study participation	Study attrition	Prognostic factor measurement	Outcome measurement	Study confounding	Statistical analysis and reporting	Overall risk of bias
Aida 2015	?	●	?	●	●	●	●
Anstee 2019	?	●	●	●	●	●	●
Balakrishnan 2020	●	●	●	●	●	●	●
Boursier 2019	●	●	?	●	●	●	●
Carli 2019	●	●	●	●	●	●	●
Chan 2015	●	●	●	●	●	●	●
Chan 2019	●	●	●	●	●	●	●
Cui 2015	●	●	●	●	●	●	●
Demir 2013	●	●	●	●	●	●	●
Goh 2015	●	●	●	●	●	●	●
Joo 2017	●	●	●	?	●	●	●
Jun 2017	●	●	●	●	●	●	●
Kakisaka 2018	●	●	●	●	●	●	●
Kao 2020	?	●	?	●	●	●	●
Kaya 2020	●	●	●	●	●	●	●
Kim 2013	?	●	?	●	●	●	●
Labenz 2018	●	●	●	●	●	●	●
Lang 2020	●	●	?	●	●	●	●
Lum 2020	●	●	●	●	●	●	●
McPherson 2013	●	●	?	●	●	●	●
Meneses 2020	●	●	?	●	●	●	●
Nasr 2016	?	●	●	●	●	●	●
Ooi 2017	●	●	?	●	●	●	●
Patel 2018	?	●	●	●	●	●	●
Perez 2013	●	●	●	●	●	●	●
Petta 2015	?	●	●	●	●	●	●
Petta 2019	●	●	●	●	●	●	●
Siddiqui 2020	?	●	●	●	●	●	●
Singh 2020	●	●	?	●	●	●	●
Treeprasertsuk 2016	●	●	●	●	●	●	●
Wong 2008	●	●	●	●	●	●	●
Wong 2010	●	●	●	●	●	●	●
Xun 2012	●	●	●	●	●	●	●
Yang 2019	●	●	●	●	●	●	●
Yoneda 2013	●	●	?	●	●	●	●
Zhou 2019	●	●	●	●	●	●	●



(3) Funnel plot for analysis publication bias



Supplementary Table 1. Summary Statistics of FIB-4 at Various Thresholds for Prediction of Advanced Fibrosis

Author (year)	No. of samples	Threshold	Advanced fibrosis (95% CI)					
			SE	SP	DOR	LR+	LR-	AUC
Threshold: 1.02–1.45								
Siddiqui, 2020	1,904	1.02	0.9 [0.87, 0.92]	0.49 [0.46, 0.52]	8.6 [6.37, 11.61]	1.76 [1.66, 1.87]	0.20 [0.15, 0.26]	0.81 [0.73, 0.89]
Anstee, 2019	3,123	1.3	0.82 [0.8, 0.84]	0.57 [0.54, 0.6]	6.03 [5.08, 7.15]	1.90 [1.76, 2.05]	0.31 [0.28, 0.35]	0.78 [0.76, 0.80]
Balakrishnan, 2020	99	1.3	0.57 [0.39, 0.73]	0.77 [0.65, 0.87]	4.5 [1.86, 10.87]	2.51 [1.46, 4.31]	0.55 [0.37, 0.82]	0.77 [0.68, 0.87]
Cui, 2015	102	1.3	0.84 [0.6, 0.97]	0.71 [0.60, 0.81]	13.11 [3.5, 49.14]	2.91 [1.97, 4.29]	0.22 [0.07, 0.63]	0.86 [0.77, 0.94]
Joo, 2017	315	1.3	0.73 [0.59, 0.84]	0.61 [0.55, 0.67]	4.2 [2.21, 7.99]	1.87 [1.49, 2.33]	0.44 [0.28, 0.69]	0.86 [0.81, 0.92]
Jun, 2017	328	1.3	0.57 [0.43, 0.69]	0.56 [0.5, 0.62]	1.66 [0.95, 2.92]	1.28 [0.99, 1.66]	0.77 [0.56, 1.05]	0.58 [0.51, 0.66]
Kaya, 2020	463	1.3	0.64 [0.53, 0.75]	0.74 [0.69, 0.78]	5.06 [3.04, 8.41]	2.45 [1.94, 3.09]	0.48 [0.36, 0.65]	0.73 [0.67, 0.79]
Ki, 2013	142	1.3	0.87 [0.74, 0.95]	0.55 [0.45, 0.65]	8.22 [3.19, 21.2]	1.94 [1.51, 2.48]	0.23 [0.10, 0.50]	0.82 [0.75, 0.88]
Labenz, 2018	261	1.3	0.68 [0.52, 0.82]	0.62 [0.55, 0.68]	3.49 [1.71, 7.11]	1.78 [1.36, 2.33]	0.51 [0.32, 0.81]	0.71 [0.60, 0.80]
Lang, 2020	95	1.3	0.84 [0.66, 0.95]	0.72 [0.59, 0.82]	13.29 [4.42, 39.98]	2.98 [1.95, 4.54]	0.22 [0.09, 0.50]	0.85 [0.78, 0.94]
McPherson, 2013a	70	1.3	0.82 [0.57, 0.96]	0.77 [0.64, 0.88]	15.94 [3.92, 64.86]	3.63 [2.11, 6.26]	0.22 [0.08, 0.64]	0.86 [0.77, 0.96]
McPherson, 2013b	235	1.3	0.8 [0.65, 0.91]	0.72 [0.65, 0.78]	10.69 [4.65, 24.62]	2.89 [2.20, 3.79]	0.27 [0.14, 0.50]	0.85 [0.79, 0.92]
Patel, 2018a	114	1.3	0.31 [0.09, 0.61]	0.16 [0.09, 0.24]	0.08 [0.02, 0.30]	0.36 [0.16, 0.82]	4.37 [2.45, 7.78]	0.25 [0.1, 0.39]
Patel, 2018b	151	1.3	0.08 [0.02, 0.19]	0.43 [0.34, 0.54]	0.06 [0.02, 0.19]	0.13 [0.05, 0.35]	2.12 [1.67, 2.69]	0.25 [0.19, 0.32]
Petta, 2019	968	1.3	0.68 [0.62, 0.73]	0.76 [0.73, 0.79]	6.76 [4.98, 9.20]	2.85 [2.44, 3.34]	0.42 [0.35, 0.50]	0.77 [0.67, 0.87]
Treprasertsuk, 2016	139	1.3	0.56 [0.21, 0.86]	0.84 [0.76, 0.90]	6.49 [1.61, 26.19]	3.43 [1.70, 6.94]	0.53 [0.25, 1.10]	0.74 [0.70, 0.78]
Wong, 2010	246	1.3	0.64 [0.5, 0.77]	0.8 [0.74, 0.85]	7.2 [3.75, 13.82]	3.21 [2.27, 4.53]	0.44 [0.31, 0.63]	0.80 [0.74, 0.87]
Xun, 2012	152	1.3	0.67 [0.45, 0.84]	0.67 [0.58, 0.75]	4.1 [1.62, 10.33]	2.03 [1.39, 2.95]	0.49 [0.27, 0.88]	0.75 [0.63, 0.87]
Lum, 2020	263	1.45	0.65 [0.54, 0.75]	0.67 [0.6, 0.74]	3.81 [2.19, 6.62]	1.98 [1.52, 2.57]	0.52 [0.37, 0.71]	0.68 [0.61, 0.75]
Singh, 2020	1,134	1.45	0.73 [0.68, 0.78]	0.64 [0.61, 0.68]	4.95 [3.75, 6.53]	2.06 [1.83, 2.30]	0.41 [0.34, 0.49]	0.77 [0.74, 0.80]
Overall			0.69 [0.59, 0.77]	0.64 [0.57, 0.71]	4.11 [2.24, 7.55]	1.96 [1.49, 2.57]	0.47 [0.33, 0.67]	0.73 [0.67, 0.80]
Heterogeneity - I ² (%)			94.4 (NA, NA)	98.4 (NA, NA)	86.7 (81.5, 90.5)	97.7 (NA, NA)	96.3 (NA, NA)	99.5 (99.5, 99.6)
p-value			<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Threshold: 1.515–2.09								
Nasr, 2016	58	1.6	0.83 [0.52, 0.98]	0.83 [0.69, 0.92]	23.75 [4.34, 129.86]	4.79 [2.43, 9.44]	0.20 [0.05, 0.71]	0.89 [0.81, 0.98]
Kakisaka, 2018	63	1.62	0.73 [0.52, 0.88]	0.73 [0.56, 0.86]	7.33 [2.37, 22.69]	2.70 [1.51, 4.82]	0.36 [0.19, 0.71]	0.78 [0.68, 0.98]
Yoneda, 2013	235	1.659	0.89 [0.75, 0.97]	0.71 [0.64, 0.77]	20.88 [7.08, 61.53]	3.09 [2.42, 3.94]	0.14 [0.05, 0.37]	0.87 [0.77, 0.97]
Siddiqui, 2020	1,904	1.95	0.47 [0.43, 0.51]	0.9 [0.88, 0.92]	7.94 [6.22, 10.14]	4.68 [3.90, 5.62]	0.58 [0.54, 0.63]	0.81 [0.73, 0.89]
Aida, 2015	148	2.09	0.76 [0.61, 0.88]	0.78 [0.69, 0.86]	11.55 [4.95, 26.94]	3.51 [2.35, 5.23]	0.30 [0.17, 0.52]	0.81 [0.74, 0.87]
Overall			0.74 [0.58, 0.85]	0.80 [0.72, 0.86]	11.97 [7.48, 19.16]	3.82 [3.00, 4.88]	0.32 [0.20, 0.51]	0.82 [0.78, 0.87]
Heterogeneity - I ² (%)			88.9 (NA, NA)	90.7 (NA, NA)	26.4 [0, 69.3]	76.3 (NA, NA)	91.5 (NA, NA)	48.3 [0, 79.5]
p-value			<0.001	<0.001	0.237	<0.001	<0.001	0.085
Threshold: 2.67								
Anstee, 2019	3,123	2.67	0.36 [0.34, 0.38]	0.93 [0.91, 0.95]	7.53 [5.74, 9.86]	5.06 [3.97, 6.44]	0.68 [0.66, 0.71]	0.78 [0.76, 0.80]
Balakrishnan, 2020	99	2.67	0.41 [0.25, 0.58]	1.00 [0.94, 1.00]	86.11 [4.95, 1499.26]	51.39 [3.16, 834.44]	0.59 [0.45, 0.77]	0.77 [0.68, 0.87]
Carti, 2019	266	2.67	0.33 [0.12, 0.62]	0.87 [0.82, 0.91]	3.3 [1.06, 10.27]	2.58 [1.22, 5.45]	0.75 [0.52, 1.08]	NA
Joo, 2017	315	2.67	0.67 [0.53, 0.79]	0.91 [0.87, 0.94]	21.18 [10.44, 42.97]	7.43 [4.85, 11.4]	0.36 [0.24, 0.52]	0.86 [0.77, 0.94]
Jun, 2017	328	2.67	0.22 [0.12, 0.34]	0.87 [0.82, 0.91]	1.84 [0.91, 3.74]	1.67 [0.95, 2.94]	0.89 [0.77, 1.03]	0.86 [0.81, 0.92]

Supplementary Table 1. Continued

Author (year)	No. of samples	Threshold	Advanced fibrosis (95% CI)					
			SE	SP	DOR	LR +	LR -	AUC
Kabbany, 2016	50	2.67	0.67 (0.09, 0.99)	0.43 (0.28, 0.58)	1.48 (0.13, 17.5)	9.24 (2.24, 37.96)	0.74 (0.56, 0.98)	0.58 (0.51, 0.66)
Kaya, 2020	463	2.67	0.15 (0.08, 0.24)	0.97 (0.95, 0.99)	5.87 (2.49, 13.83)	5.07 (2.36, 10.90)	0.87 (0.79, 0.95)	0.73 (0.67, 0.79)
Labenz, 2018	261	2.67	0.39 (0.24, 0.56)	0.88 (0.83, 0.92)	4.78 (2.26, 10.1)	3.27 (1.95, 5.50)	0.68 (0.53, 0.88)	0.71 (0.69, 0.73)
Patel, 2018a	114	2.67	0.23 (0.05, 0.54)	0.98 (0.93, 1.00)	14.85 (2.21, 99.66)	10.2 (2.22, 46.81)	0.76 (0.56, 1.04)	0.62 (0.49, 0.74)
Patel, 2018b	151	2.67	0.56 (0.41, 0.7)	0.98 (0.93, 1.00)	61.15 (13.6, 274.96)	22.26 (6.39, 77.50)	0.45 (0.33, 0.61)	0.76 (0.69, 0.83)
Petta, 2015a	179	2.67	0.51 (0.35, 0.67)	0.97 (0.93, 0.99)	35.17 (10.94, 113.1)	15.81 (6.08, 41.1)	0.50 (0.36, 0.68)	0.79 (0.70, 0.87)
Petta, 2015b	142	2.67	0.24 (0.1, 0.44)	0.96 (0.9, 0.99)	6.87 (2.00, 23.65)	5.18 (1.86, 14.43)	0.78 (0.63, 0.97)	0.70 (0.58, 0.81)
Petta, 2019	988	2.67	0.22 (0.18, 0.28)	0.97 (0.95, 0.98)	8.06 (4.91, 13.24)	6.38 (4.08, 9.96)	0.80 (0.75, 0.85)	0.77 (0.72, 0.82)
Singh, 2020	1,134	2.67	0.45 (0.40, 0.50)	0.93 (0.91, 0.95)	11.18 (7.89, 15.85)	6.55 (4.94, 8.70)	0.59 (0.53, 0.65)	0.77 (0.74, 0.80)
Wong, 2010	246	2.67	0.21 (0.12, 0.34)	0.95 (0.91, 0.98)	5.48 (2.18, 13.83)	4.40 (2.00, 9.71)	0.82 (0.71, 0.94)	0.8 (0.74, 0.87)
Xun, 2012	152	2.67	0.38 (0.19, 0.59)	0.96 (0.91, 0.99)	14.76 (4.37, 49.87)	8.91 (3.41, 23.25)	0.64 (0.47, 0.88)	0.75 (0.63, 0.87)
Yang, 2019	453	2.67	0.18 (0.12, 0.26)	0.96 (0.94, 0.98)	5.86 (2.82, 12.19)	4.85 (2.52, 9.34)	0.84 (0.77, 0.92)	0.57 (0.46, 0.68)
Yoneda, 2013	235	2.67	0.63 (0.46, 0.78)	0.88 (0.83, 0.92)	12.97 (5.89, 28.57)	5.29 (3.37, 8.29)	0.42 (0.27, 0.63)	0.87 (0.85, 0.89)
Overall			0.34 (0.27, 0.42)	0.95 (0.92, 0.96)	9.32 (6.26, 13.87)	6.46 (4.66, 8.95)	0.69 (0.62, 0.77)	0.74 (0.70, 0.76)
Heterogeneity - I ² (%)			92.1 (NA, NA)	93.1 (NA, NA)	64.9 (44.2, 77.9)	94.2 (NA, NA)	96.4 (NA, NA)	99.7 (99.7, 99.8)
p-value			<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Threshold: 3.25								
Boursier, 2019	938	3.25	0.92 (0.89, 0.94)	0.96 (0.94, 0.98)	303.44 (170.23, 540.89)	25.54 (16.59, 39.32)	0.08 (0.06, 0.12)	0.76 (0.71, 0.81)
Chan, 2019	583	3.25	0.23 (0.15, 0.32)	0.97 (0.95, 0.98)	9.04 (4.52, 18.08)	7.23 (3.91, 13.36)	0.79 (0.71, 0.88)	0.75 (0.64, 0.87)
Ki, 2013	142	3.25	0.48 (0.33, 0.63)	0.93 (0.86, 0.97)	11.65 (4.45, 30.52)	6.55 (3.02, 14.23)	0.56 (0.42, 0.74)	0.83 (0.75, 0.88)
Lang, 2020	95	3.25	0.39 (0.22, 0.58)	0.97 (0.89, 1.00)	19.58 (4.02, 95.31)	12.38 (2.95, 51.97)	0.63 (0.47, 0.83)	0.85 (0.78, 0.94)
Lum, 2020	263	3.25	0.21 (0.13, 0.32)	0.91 (0.86, 0.95)	2.82 (1.34, 5.91)	2.43 (1.29, 4.56)	0.86 (0.76, 0.97)	0.68 (0.61, 0.75)
McPherson, 2013a	70	3.25	0.35 (0.14, 0.62)	0.98 (0.90, 1.00)	28.36 (3.10, 259.77)	18.70 (2.41, 144.62)	0.65 (0.46, 0.93)	0.86 (0.77, 0.96)
McPherson, 2013b	235	3.25	0.20 (0.09, 0.35)	0.98 (0.95, 0.99)	11.52 (3.28, 40.43)	9.46 (2.99, 29.94)	0.82 (0.70, 0.95)	0.85 (0.79, 0.92)
Perez, 2013	243	3.25	0.56 (0.35, 0.75)	0.89 (0.84, 0.93)	10.00 (4.19, 23.86)	5.00 (3.01, 8.29)	0.50 (0.32, 0.76)	0.74 (0.65, 0.84)
Xun, 2012	152	3.25	0.21 (0.07, 0.42)	0.97 (0.92, 0.99)	8.16 (2.01, 33.1)	6.66 (1.92, 23.04)	0.81 (0.66, 1.0)	0.75 (0.63, 0.87)
Overall			0.39 (0.22, 0.59)	0.95 (0.93, 0.97)	14.23 (5.92, 34.19)	8.97 (4.87, 16.50)	0.63 (0.45, 0.86)	0.76 (0.7, 0.88)
Heterogeneity - I ² (%)			94.2 (NA, NA)	91 (NA, NA)	91.3 (86.7, 94.3)	94.2 (NA, NA)	95.4 (NA, NA)	98.7 (98.3, 99)
p-value			<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

FIB-4, fibrosis-4; CI, confidence interval; SE, sensitivity; SP, specificity; DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR-, negative likelihood ratio; AUC, area under the curve; NA, not available.

Supplementary Table 2. Summary Statistics of NFS at Various Thresholds for Prediction of Advanced Fibrosis

Author (year)	No. of samples	Threshold	Advanced fibrosis (95% CI)					
			SE	SP	DOR	LR+	LR-	AUC
Threshold: -1.98 to -1.036								
Siddiqui, 2020	1,904	-1.98	0.90 (0.87, 0.92)	0.41 (0.38, 0.44)	6.21 (4.59, 8.39)	1.52 (1.44, 1.60)	0.25 (0.19, 0.32)	0.80 (0.71, 0.88)
Anstee, 2019	2,417	-1.455	0.89 (0.88, 0.9)	0.37 (0.33, 0.41)	4.74 (3.75, 5.98)	1.41 (1.32, 1.52)	0.30 (0.25, 0.35)	0.74 (0.72, 0.76)
Balakrishnan, 2020	99	-1.455	0.81 (0.65, 0.92)	0.66 (0.53, 0.78)	8.37 (3.15, 22.22)	2.35 (1.61, 3.43)	0.30 (0.15, 0.58)	0.79 (0.69, 0.88)
Demir, 2013	120	-1.455	0.75 (0.48, 0.93)	0.93 (0.87, 0.97)	41.57 (10.59, 163.12)	10.29 (4.88, 21.71)	0.29 (0.13, 0.63)	0.96 (0.92, 0.99)
Goh, 2015a	238	-1.455	0.90 (0.82, 0.95)	0.19 (0.13, 0.27)	2.08 (0.92, 4.69)	1.11 (0.99, 1.23)	0.55 (0.27, 1.10)	NA
Goh, 2015b	263	-1.455	0.62 (0.47, 0.76)	0.65 (0.58, 0.71)	3.02 (1.55, 5.86)	1.75 (1.31, 2.34)	0.59 (0.40, 0.86)	NA
Joo, 2017	315	-1.455	0.87 (0.76, 0.95)	0.60 (0.54, 0.66)	10.29 (4.48, 23.61)	2.16 (1.81, 2.59)	0.22 (0.11, 0.44)	0.84 (0.78, 0.90)
Jun, 2017	328	-1.455	0.53 (0.4, 0.66)	0.67 (0.61, 0.72)	2.30 (1.30, 4.05)	1.60 (1.20, 2.14)	0.70 (0.53, 0.93)	0.64 (0.56, 0.72)
Kaya, 2020	463	-1.455	0.72 (0.6, 0.81)	0.63 (0.58, 0.68)	4.31 (2.55, 7.29)	1.93 (1.60, 2.33)	0.45 (0.32, 0.65)	0.71 (0.65, 0.77)
Ki, 2013	142	-1.455	0.91 (0.79, 0.98)	0.43 (0.33, 0.53)	7.83 (2.6, 23.57)	1.58 (1.30, 1.92)	0.22 (0.09, 0.56)	0.79 (0.72, 0.86)
Labenz, 2018	261	-1.455	0.68 (0.52, 0.82)	0.65 (0.58, 0.71)	4.00 (1.96, 8.17)	1.94 (1.47, 2.55)	0.50 (0.32, 0.78)	0.73 (0.68, 0.78)
Lang, 2020	95	-1.455	0.81 (0.63, 0.93)	0.72 (0.59, 0.82)	10.65 (3.75, 30.26)	2.80 (1.83, 4.28)	0.28 (0.14, 0.57)	0.86 (0.75, 0.94)
Lum, 2020	263	-1.455	0.75 (0.64, 0.84)	0.65 (0.58, 0.72)	5.58 (3.09, 10.07)	2.13 (1.69, 2.69)	0.39 (0.26, 0.57)	0.65 (0.58, 0.73)
McPherson, 2013a	70	-1.455	0.82 (0.57, 0.96)	0.51 (0.37, 0.65)	4.85 (1.25, 18.85)	1.64 (1.15, 2.34)	0.38 (0.14, 1.01)	0.85 (0.74, 0.96)
McPherson, 2013b	235	-1.455	0.71 (0.54, 0.84)	0.65 (0.58, 0.72)	4.48 (2.15, 9.33)	2.00 (1.52, 2.63)	0.46 (0.29, 0.74)	0.80 (0.72, 0.88)
Patel, 2018a	108	-1.455	0.08 (0.00, 0.36)	0.35 (0.25, 0.45)	0.04 (0.01, 0.36)	0.16 (0.04, 0.75)	2.56 (1.84, 3.55)	0.22 (0.12, 0.32)
Patel, 2018b	147	-1.455	0.02 (0.00, 0.10)	0.62 (0.52, 0.72)	0.03 (0.00, 0.24)	0.02 (0.00, 0.40)	1.60 (1.36, 1.87)	0.32 (0.27, 0.37)
Petta, 2019	968	-1.455	0.74 (0.69, 0.79)	0.70 (0.66, 0.73)	6.63 (4.84, 9.08)	2.44 (2.14, 2.79)	0.37 (0.30, 0.46)	0.76 (0.71, 0.81)
Singh, 2020	1,057	-1.455	0.64 (0.59, 0.69)	0.70 (0.67, 0.74)	4.22 (3.21, 5.56)	2.15 (1.88, 2.47)	0.51 (0.44, 0.59)	0.72 (0.69, 0.75)
Treeraprasertsuk, 2016	139	-1.455	0.89 (0.52, 1.00)	0.48 (0.39, 0.57)	7.29 (0.89, 59.99)	1.63 (1.20, 2.21)	0.31 (0.07, 1.39)	0.66 (0.61, 0.71)
Wong, 2008	128	-1.455	0.39 (0.17, 0.64)	0.81 (0.74, 0.87)	2.76 (0.98, 7.77)	2.08 (1.08, 3.98)	0.74 (0.51, 1.08)	0.64 (0.49, 0.79)
Wong, 2010	246	-1.455	0.73 (0.60, 0.84)	0.69 (0.62, 0.76)	6.22 (3.19, 12.12)	2.38 (1.82, 3.10)	0.39 (0.25, 0.61)	0.75 (0.67, 0.83)
Xun, 2012	152	-1.455	0.38 (0.19, 0.59)	0.86 (0.79, 0.91)	3.67 (1.40, 9.62)	2.64 (1.37, 5.09)	0.72 (0.52, 0.99)	0.65 (0.52, 0.78)
Overall			0.70 (0.57, 0.80)	0.61 (0.53, 0.69)	3.77 (2.16, 6.56)	1.83 (1.46, 2.28)	0.48 (0.33, 0.70)	0.72 (0.66, 0.79)
Heterogeneity - I^2 (%)			96.2 (NA, NA)	98.4 (NA, NA)	75.7 (65.1, 83.1)	97.6 (NA, NA)	95.6 (NA, NA)	99.7 (99.6, 99.7)
p-value			<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Threshold: -0.126 to 0.19								
Nasr, 2016	58	-0.126	0.83 (0.52, 0.98)	0.83 (0.69, 0.92)	23.75 (4.34, 129.86)	4.79 (2.43, 9.44)	0.20 (0.05, 0.71)	0.85 (0.74, 0.97)
Siddiqui, 2020	1,904	0.19	0.43 (0.39, 0.47)	0.90 (0.88, 0.92)	6.78 (5.30, 8.66)	4.29 (3.56, 5.17)	0.63 (0.58, 0.68)	0.80 (0.71, 0.88)
Overall			0.61 (0.28, 0.86)	0.87 (0.79, 0.92)	10.79 (3.65, 31.84)	4.79 (3.13, 7.35)	0.44 (0.20, 0.97)	0.80 (0.78, 0.88)
Heterogeneity - I^2 (%)			66.6 (NA, NA)	0 (NA, NA)	51.2 (0, 87.6)	0 (NA, NA)	56.8 (NA, NA)	0 (NA, NA)
p-value			0.015	0.111	0.152	0.538	0.033	0.327
Threshold: 0.675 to 0.735								
Chan, 2019	583	0.675	0.17 (0.1, 0.25)	0.99 (0.98, 1.00)	21.6 (7.09, 65.79)	16.49 (5.98, 45.45)	0.83 (0.76, 0.91)	0.70 (0.57, 0.83)
Lum, 2020	263	0.675	0.20 (0.12, 0.30)	0.95 (0.91, 0.98)	4.83 (2.03, 11.48)	3.94 (1.85, 8.38)	0.83 (0.74, 0.94)	0.65 (0.58, 0.73)
Anstee, 2019	2,417	0.676	0.38 (0.36, 0.40)	0.89 (0.86, 0.92)	4.99 (3.70, 6.73)	3.43 (2.65, 4.45)	0.69 (0.66, 0.73)	0.74 (0.72, 0.76)
Balakrishnan, 2020	99	0.676	0.32 (0.18, 0.50)	0.95 (0.86, 0.99)	9.44 (2.45, 36.37)	5.92 (1.94, 18.05)	0.71 (0.56, 0.89)	0.79 (0.69, 0.88)
Boursier, 2019	938	0.676	0.90 (0.86, 0.92)	0.94 (0.92, 0.96)	140.01 (86.25, 227.26)	15.32 (10.95, 21.43)	0.11 (0.08, 0.15)	0.72 (0.67, 0.77)

Supplementary Table 2. Continued

Author (year)	No. of samples	Threshold	Advanced fibrosis [95% CI]						AUC
			SE	SP	DOR	LR+	LR-		
Carli, 2019	266	0.676	0.10 (0.00, 0.44)	0.97 (0.93, 0.99)	3.17 (0.36, 28.1)	3.80 (0.74, 19.34)	0.89 (0.70, 1.13)	NA	
Chan, 2015	147	0.676	0.40 (0.05, 0.85)	0.97 (0.89, 1.00)	21.00 (2.16, 204.61)	11.00 (2.35, 51.36)	0.60 (0.30, 1.19)	NA	
Demir, 2013	120	0.676	0.19 (0.04, 0.46)	1.00 (0.97, 1.00)	54.19 (2.65, 1106.91)	43.23 (2.33, 800.47)	0.79 (0.62, 1.01)	0.96 (0.92, 0.99)	
Goh, 2015a	238	0.676	0.49 (0.39, 0.60)	0.86 (0.78, 0.91)	5.82 (3.07, 11.02)	3.37 (2.12, 5.34)	0.59 (0.47, 0.73)	NA	
Goh, 2015b	263	0.676	0.13 (0.05, 0.27)	0.97 (0.94, 0.99)	4.64 (1.48, 14.54)	4.12 (1.51, 11.22)	0.88 (0.78, 1.00)	NA	
Joo, 2017	315	0.676	0.47 (0.34, 0.61)	0.93 (0.90, 0.96)	12.82 (6.22, 26.39)	7.05 (4.15, 11.99)	0.56 (0.43, 0.72)	0.84 (0.78, 0.90)	
Jun, 2017	328	0.676	0.08 (0.03, 0.18)	0.98 (0.96, 0.99)	4.78 (1.34, 17.08)	4.40 (1.39, 13.90)	0.92 (0.85, 1.00)	0.64 (0.56, 0.72)	
Kaya, 2020	463	0.676	0.15 (0.08, 0.24)	0.96 (0.94, 0.98)	4.57 (2.03, 10.3)	4.02 (1.96, 8.25)	0.88 (0.80, 0.96)	0.71 (0.65, 0.77)	
Ki, 2013	142	0.676	0.57 (0.41, 0.71)	0.84 (0.76, 0.91)	7.02 (3.15, 15.66)	3.52 (2.09, 5.94)	0.51 (0.37, 0.72)	0.79 (0.72, 0.86)	
Labenz, 2018	261	0.676	0.34 (0.20, 0.51)	0.93 (0.89, 0.96)	7.09 (3.09, 16.28)	4.92 (2.60, 9.29)	0.70 (0.56, 0.87)	0.73 (0.68, 0.78)	
Lang, 2020	95	0.676	0.39 (0.22, 0.58)	0.98 (0.92, 1.00)	39.79 (4.86, 326.07)	16.92 (3.28, 87.24)	0.62 (0.47, 0.82)	0.86 (0.75, 0.94)	
McPherson, 2013a	70	0.676	0.47 (0.23, 0.72)	0.98 (0.90, 1.00)	46.22 (5.14, 415.48)	17.00 (3.25, 88.67)	0.54 (0.34, 0.84)	0.85 (0.74, 0.96)	
McPherson, 2013b	235	0.676	0.27 (0.14, 0.43)	0.97 (0.93, 0.99)	11.49 (3.95, 33.39)	8.21 (3.33, 20.24)	0.75 (0.62, 0.90)	0.80 (0.72, 0.88)	
Patel, 2018a	108	0.676	0.46 (0.19, 0.75)	0.98 (0.93, 1.00)	39.86 (6.75, 235.2)	17.82 (4.63, 68.53)	0.55 (0.33, 0.89)	0.72 (0.56, 0.87)	
Patel, 2018b	147	0.676	0.67 (0.53, 0.80)	0.83 (0.74, 0.90)	10.17 (4.61, 22.4)	3.89 (2.41, 6.28)	0.39 (0.26, 0.59)	0.76 (0.68, 0.83)	
Perez, 2013	243	0.676	0.52 (0.32, 0.71)	0.87 (0.82, 0.91)	7.23 (3.08, 16.97)	3.94 (2.40, 6.46)	0.55 (0.37, 0.81)	0.72 (0.6, 0.83)	
Petta, 2015a	179	0.676	0.34 (0.2, 0.51)	0.99 (0.96, 1.00)	71.04 (8.96, 563.13)	31.99 (6.17, 165.79)	0.66 (0.53, 0.82)	0.80 (0.71, 0.89)	
Petta, 2015b	142	0.676	0.14 (0.04, 0.32)	1.00 (0.97, 1.00)	40.06 (2.09, 767.77)	34.2 (1.89, 617.79)	0.85 (0.75, 0.99)	0.73 (0.62, 0.83)	
Petta, 2019	968	0.676	0.16 (0.12, 0.21)	0.97 (0.95, 0.98)	5.93 (3.49, 10.09)	5.05 (3.11, 8.22)	0.86 (0.81, 0.91)	0.76 (0.71, 0.81)	
Singh, 2020	1,057	0.676	0.64 (0.59, 0.69)	0.70 (0.67, 0.74)	4.22 (3.21, 5.56)	2.15 (1.87, 2.46)	0.51 (0.43, 0.59)	0.72 (0.69, 0.75)	
Wong, 2008	128	0.676	0.00 (0.00, 0.19)	0.99 (0.95, 1.00)	1.54 (0.07, 33.34)	1.52 (0.07, 30.61)	0.99 (0.91, 1.07)	0.64 (0.49, 0.79)	
Wong, 2010	246	0.676	0.18 (0.09, 0.30)	0.96 (0.93, 0.99)	5.68 (2.05, 15.74)	4.69 (1.92, 11.31)	0.84 (0.74, 0.96)	0.75 (0.67, 0.83)	
Xun, 2012	152	0.676	0.08 (0.01, 0.27)	1.00 (0.97, 1.00)	28.56 (1.33, 614.66)	25.8 (1.27, 521.32)	0.90 (0.79, 1.03)	0.65 (0.52, 0.78)	
Yang, 2019	453	0.676	0.20 (0.13, 0.28)	0.92 (0.88, 0.94)	2.75 (1.53, 4.96)	3.39 (1.45, 3.94)	0.87 (0.79, 0.95)	0.52 (0.41, 0.63)	
Yoneda, 2013	235	0.676	0.68 (0.51, 0.82)	0.88 (0.82, 0.92)	15.62 (6.97, 34.98)	5.72 (3.70, 8.85)	0.36 (0.22, 0.57)	0.84 (0.79, 0.89)	
Yoneda, 2013	235	0.735	0.68 (0.51, 0.82)	0.88 (0.83, 0.92)	16.39 (7.29, 36.87)	5.49 (3.57, 8.43)	0.36 (0.23, 0.57)	0.84 (0.79, 0.89)	
Overall			0.31 (0.23, 0.41)	0.95 (0.93, 0.97)	10.17 (7.06, 14.63)	7.29 (5.34, 9.93)	0.71 (0.63, 0.81)	0.73 (0.71, 0.81)	
Heterogeneity - I ² (%)			96 (NA, NA)	96.6 (NA, NA)	84.5 (79.6, 88.3)	92.6 (NA, NA)	96.9 (NA, NA)	99.6 (99.5, 99.6)	
p-value			<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	

NFS, nonalcoholic fatty liver disease fibrosis score; CI, confidence interval; SE, sensitivity; SP, specificity; DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR-, negative likelihood ratio; AUC, area under the curve; NA, not available.

Supplementary Table 3. Summary Statistics of FIB-4 at Various Thresholds for Prediction of Significant Fibrosis


Author (year)	No. of samples	Threshold	SE	SP	DOR	LR+	LR-	AUC
Threshold: 0.66–0.89								
Kao, 2020	73	0.66	0.55 [0.36, 0.74]	0.86 [0.73, 0.95]	7.79 [2.52, 24.13]	4.04 [1.79, 9.12]	0.51 [0.34, 0.79]	0.72 [0.65, 0.80]
Ooi, 2017a	101	0.74	0.78 [0.56, 0.93]	0.47 [0.36, 0.59]	3.25 [1.10, 9.62]	1.48 [1.10, 2.01]	0.45 [0.20, 1.03]	0.64 [0.47, 0.81]
Ooi, 2017b	53	0.74	0.86 [0.42, 1.00]	0.52 [0.37, 0.67]	6.55 [0.73, 58.76]	1.79 [1.16, 2.74]	0.27 [0.04, 1.71]	0.77 [0.62, 0.92]
Zhou, 2019	207	0.89	0.66 [0.46, 0.82]	0.58 [0.50, 0.65]	2.61 [1.15, 5.93]	1.55 [1.13, 2.13]	0.59 [0.35, 0.99]	0.62 [0.37, 0.88]
Overall			0.69 [0.55, 0.80]	0.61 [0.44, 0.76]	3.58 [1.96, 6.53]	1.79 [1.26, 2.55]	0.50 [0.35, 0.70]	0.66 [0.61, 0.77]
Heterogeneity - I ² (%)			4.2 (NA, NA)	87 (NA, NA)	0 [0, 82.8]	85.6 (NA, NA)	57.8 (NA, NA)	0 [0, 74.3]
p-value			0.253	0.001	0.445	<0.001	0.021	0.618
Threshold: 1.4–1.9								
Kakisaka, 2018	63	1.4	0.68 [0.51, 0.81]	0.78 [0.56, 0.93]	7.48 [2.27, 24.61]	3.10 [1.38, 6.94]	0.41 [0.25, 0.68]	0.76 [0.75, 0.78]
Kao, 2020	73	1.9	0.62 [0.42, 0.79]	0.59 [0.43, 0.74]	2.36 [0.90, 6.18]	1.51 [0.96, 2.39]	0.64 [0.37, 1.08]	0.61 [0.48, 0.73]
Overall			0.65 [0.53, 0.75]	0.66 [0.51, 0.79]	3.69 [1.61, 8.49]	1.94 [1.21, 3.09]	0.52 [0.35, 0.78]	0.74 [0.54, 0.85]
Heterogeneity - I ² (%)			0 (NA, NA)	11.2 (NA, NA)	54 [0, 88.7]	76.8 (NA, NA)	0 (NA, NA)	84.3 [35.7, 96.2]
p-value			0.64	0.122	0.14	0.004	0.296	0.012
Threshold: 2.67–3.25								
Meneses, 2020	50	2.67	0.11 [0.00, 0.48]	0.98 [0.87, 1.00]	5.13 [0.29, 90.7]	12.6 [0.55, 286.89]	0.86 [0.66, 1.11]	0.69 [0.61, 0.76]
Ooi, 2017a	101	3.25	0.04 [0.00, 0.22]	0.99 [0.93, 1.00]	3.55 [0.21, 59.00]	9.87 [0.41, 234.59]	0.94 [0.84, 1.04]	0.64 [0.54, 0.74]
Overall			0.06 [0.02, 0.22]	0.98 [0.94, 1.00]	4.25 [0.57, 31.68]	10.82 [0.47, 257.67]	0.93 [0.85, 1.02]	0.67 [0.61, 0.73]
Heterogeneity - I ² (%)			0 (NA, NA)	0 (NA, NA)	0 (NA, NA)	-	0 (NA, NA)	0 (NA, NA)
p-value			0.492	0.652	0.419	-	0.857	0.45

FIB-4, fibrosis-4; CI, confidence interval; SE, sensitivity; SP, specificity; DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR-, negative likelihood ratio; AUC, area under the curve; NA, not available.


Supplementary Table 4. Summary Statistics of NFS at Various Thresholds for Prediction of Significant Fibrosis

Author (year)	No. of samples	Threshold	SE	SP	DOR	LR+	LR-	AUC
Threshold: -3.168 to -1.455								
Zhou, 2019	207	-3.168	0.76 [0.56, 0.90]	0.46 [0.39, 0.54]	2.68 [1.09, 6.6]	1.40 [1.09, 1.79]	0.52 [0.26, 1.01]	0.60 [0.45, 0.75]
Wong, 2008	128	-1.455	0.37 [0.22, 0.53]	0.84 [0.77, 0.90]	3.10 [1.39, 6.91]	2.32 [1.30, 4.14]	0.75 [0.58, 0.96]	0.67 [0.60, 0.74]
Overall			0.57 [0.28, 0.81]	0.68 [0.37, 0.88]	2.82 [1.53, 5.18]	1.78 [1.11, 2.84]	0.63 [0.42, 0.94]	0.61 [0.58, 0.72]
Heterogeneity - I ² (%)			80.6 (NA, NA)	95.1 (NA, NA)	0 (NA, NA)	77.2 (NA, NA)	66.9 (NA, NA)	0 (NA, NA)
p-value			0.002	<0.001	0.816	0.003	0.015	0.404
Threshold: 0.676								
Meneses, 2020	50	0.676	0.22 [0.03, 0.60]	0.8 [0.65, 0.91]	1.18 [0.20, 6.79]	1.23 [0.36, 4.22]	0.94 [0.63, 1.38]	0.43 [0.36, 0.5]
Ooi, 2017a	101	0.676	0.09 [0.01, 0.28]	0.88 [0.79, 0.95]	0.73 [0.15, 3.65]	0.86 [0.23, 3.23]	1.01 [0.86, 1.19]	0.62 [0.53, 0.7]
Wong, 2008	128	0.676	0.00 [0.00, 0.09]	0.98 [0.94, 1.00]	0.58 [0.03, 12.24]	0.58 [0.02, 11.85]	1.00 [0.96, 1.05]	0.67 [0.62, 0.72]
Overall			0.04 [0.01, 0.25]	0.92 [0.77, 0.98]	0.52 [0.07, 3.59]	0.54 [0.08, 3.49]	1.03 [0.96, 1.12]	0.53 [0.42, 0.73]
Heterogeneity - I ² (%)			62.2 (NA, NA)	82.4 (NA, NA)	0 [0, 9.6]	0 (NA, NA)	0 (NA, NA)	93.6 [84.6, 97.3]
p-value			0.602	0.005	0.891	0.994	0.558	<0.001
Threshold: 1.292								
Ooi, 2017a	101	1.292	0.78 [0.56, 0.93]	0.37 [0.26, 0.49]	2.13 [0.71, 6.35]	1.24 [0.94, 1.63]	0.58 [0.25, 1.33]	0.62 [0.55, 0.68]
Ooi, 2017b	53	1.292	0.86 [0.42, 1.00]	0.17 [0.08, 0.31]	1.26 [0.13, 11.99]	1.03 [0.74, 1.44]	0.82 [0.12, 5.60]	0.70 [0.64, 0.77]
Overall			0.81 [0.59, 0.92]	0.27 [0.16, 0.44]	1.65 [0.50, 5.36]	1.12 [0.87, 1.44]	0.67 [0.26, 1.73]	0.67 [0.57, 0.75]
Heterogeneity - I ² (%)			0 (NA, NA)	62 (NA, NA)	0 (NA, NA)	23.6 (NA, NA)	0 (NA, NA)	71.9 [0, 93.7]
p-value			0.668	0.023	0.682	0.103	0.783	0.059


NFS, nonalcoholic fatty liver disease fibrosis score; CI, confidence interval; SE, sensitivity; SP, specificity; DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR-, negative likelihood ratio; AUC, area under the curve; NA, not available.




Supplementary Fig. 1. Forest plot of fibrosis-4 (FIB-4) index for predicting advanced fibrosis; sensitivity and specificity of FIB-4 index.



Supplementary Fig. 2. Forest plot NAFLD fibrosis score (NFS) for predicting advanced fibrosis; sensitivity and specificity of NFS. NAFLD, nonalcoholic fatty liver disease.



Supplementary Fig. 3. Forest plot of fibrosis-4 (FIB-4) index for predicting significant fibrosis; sensitivity and specificity of FIB-4 index.



Supplementary Fig. 4. Forest plot NAFLD fibrosis score (NFS) for predicting significant fibrosis; sensitivity and specificity of NFS. NAFLD, nonalcoholic fatty liver disease.